SAN DIEGO, Oct. 4, 2016 /PRNewswire/ -- Trovagene, Inc.
(NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA)
molecular diagnostics, announced today that it has been selected by
the Pancreatic Cancer Action Network as the liquid biopsy provider
to participate in Precision Promise, the first large-scale
precision medicine trial designed to transform outcomes for
patients with pancreatic cancer.
"Trovagene was chosen as the Precision Promise liquid biopsy
partner for their leadership and innovation in applying KRAS
as a real-time indicator of response to therapy," said Lynn Matrisian, PhD, MBA, Chief Research
Officer. "In partnership with Trovagene, we aim to evolve the
way diagnostics are used to optimize treatment and improve patient
survival."
The Pancreatic Cancer Action Network is the leading non-profit
organization committed to increasing survival for people diagnosed
with pancreatic cancer, and is making an initial investment of
$35 million to accelerate the
clinical trial process to bring promising therapies to patients
faster.
As a founding member of the initial Precision Promise Industry
Working Group, Trovagene will contribute to sub-study design and
future study objectives. The Trovera™ liquid biopsy test will be
used as a dynamic tool throughout the course of patient treatment
with experimental therapies.
"We're excited to partner with the Pancreatic Cancer Action
Network on this unprecedented initiative. This further
validates our approach to how quantitative liquid biopsy testing
can be used in real-time to optimize treatment decisions and the
timing of treatment changes," said Mark
Erlander, PhD, Chief Scientific Officer of Trovagene.
About Pancreatic Cancer and Precision Promise
Pancreatic cancer is the third-leading cause of cancer related
death in the United States and is
anticipated to become the second around 2020. The disease kills
more people than breast cancer and has a five-year survival of just
8 percent. Nationally, only 4 percent of pancreatic cancer patients
enroll in clinical trials.
In order to change the pancreatic cancer treatment paradigm,
Precision Promise will investigate multiple treatment options,
called sub-studies, under one clinical trial design that utilizes
an individualized treatment approach based on the molecular profile
of a patient and their tumor.
About Trovagene, Inc.
Headquartered in San Diego,
California, Trovagene is leveraging its proprietary
Precision Cancer Monitoring® (PCM) technology for the detection and
monitoring of circulating tumor DNA (ctDNA) in urine and blood. The
Company's technology detects and quantitates oncogene mutations in
cancer patients for improved disease management. Trovagene's PCM
technology is designed to provide important clinical information
beyond the current standard of care, and is protected by
significant intellectual property including multiple issued patents
and pending patent applications globally.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of words
such as "anticipate," "believe," "forecast," "estimated" and
"intend" or other similar terms or expressions that concern
Trovagene's expectations, strategy, plans or intentions. These
forward-looking statements are based on Trovagene's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our need for additional financing; uncertainties
of patent protection and litigation; clinical trials involve a
lengthy and expensive process with an uncertain outcome, and
results of earlier studies and trials may not be predictive of
future trial results; uncertainties of government or fourth party
payer reimbursement; limited sales and marketing efforts and
dependence upon fourth parties; and risks related to failure to
obtain FDA clearances or approvals and noncompliance with FDA
regulations. There are no guarantees that any of our technologies
or products will be utilized by oncologists or prove to be
commercially successful, or that Trovagene's strategy to design its
PCM platform to report on clinically actionable cancer genes will
ultimately be successful or result in better reimbursement
outcomes. Trovagene does not undertake an obligation to update or
revise any forward-looking statement. Investors should read
the risk factors set forth in Trovagene's Form 10-K for the year
ended December 31, 2015 and other
periodic reports filed with the Securities and Exchange
Commission.
Trovagene Contacts:
Beth
Anderson
VP, Finance &
Administration
|
|
Vicki
Kelemen
Sr. Director,
Marketing Communications
|
858-952-7593
|
|
858-952-7652
|
ir@trovagene.com
|
|
vkelemen@trovagene.com
|
Logo - http://photos.prnewswire.com/prnh/20160520/370471LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/trovagenes-liquid-biopsy-in-groundbreaking-national-initiative-to-transform-outcomes-for-pancreatic-cancer-patients-300338559.html
SOURCE Trovagene, Inc.